Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment
- Author
- VINCENT, Jean-Louis1 ; BERNARD, Gordon R2 ; WONG, Kar9 ; SUNDIN, David P9 ; TURLO, Mary Ann9 ; JANES, Jonathan9 ; BEALE, Richard3 ; DOIG, Christopher4 ; PUTENSEN, Christian5 ; DHAINAUT, Jean-Francois6 ; ARTIGAS, Antonio7 ; FUMAGALLI, Roberto8 ; MACIAS, William; WRIGHT, Theressa9
[1] Department of Intensive Care, Erasme University Hospital and University of Brussels, Brussels, Belgium
[2] Division of Allergy, Pulmonary and Critical Care Medicine Vanderbit University School of Medicine, Nashville, TN, United States
[3] Intensive Care Unit, Guy's and St Thomas' Hospital, London, United Kingdom
[4] Departments of Critical Care Medicine, Medicine and Community Heath Sciences, University of Calgary, Calgary, AB, Canada
[5] Department of Anesthesia and Intensive Care Medicine, University of Bonn, Bonn, Germany
[6] Service de Réanimation Médicale, Centre Hospitalo-Universitaire Cochin Port-Royal, AP-HP, Paris V University, Paris, France
[7] Critical Care Center, Sabadell Hospital, Red CIRA C03/063 University Institute Parc Tauli, Autonomous University of Barcelona, Sabadell, Spain
[8] Facolta di Medicina e Chimrgia, Università degli Studi di Milano-Bicocca, Dipartimento di Anestesia e Rianimazione, Ospedali Riuniti di Bergamo, Italy
[9] Ully Research Laboratories, Eli Lilly, Indianapolis, IN, United States
ENHANCE Study Group - Source
Critical care medicine. 2005, Vol 33, Num 10, pp 2266-2277, 12 p ; ref : 14 ref
- CODEN
- CCMDC7
- ISSN
- 0090-3493
- Scientific domain
- Anesthesia, intensive care
- Publisher
- Lippincott, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- ENHANCE activated protein C clinical trial drotrecogin alfa (activated) early treatment severe sepsis
- Keyword (fr)
- Anticoagulant Drotrécogine alfa Infection Protéine C Réanimation Septique syndrome Soin intensif Survie Traitement
- Keyword (en)
- Anticoagulant Drotrecogin alfa Infection Protein C Resuscitation Sepsis syndrome Intensive care Survival Treatment
- Keyword (es)
- Anticoagulante Drotrecogina alfa Infección Proteína C Reanimación Séptico síndrome Cuidado intensivo Sobrevivencia Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02G Blood. Blood coagulation. Reticuloendothelial system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B27 Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy / 002B27B Intensive care medicine / 002B27B10 Emergency and intensive care: infection, septic shock
- Discipline
- Anaesthesia. Reanimation. Transfusion. Cell therapy and gene therapy Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17192454
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1097/01.CCM.0000181729.46010.83 
https://dx.doi.org/10.1097/01.CCM.0000181729.46010.83
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1097\/01.CCM.0000181729.46010.83\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Critical care medicine\";s:9:\"\u0000*\u0000stitle\";s:14:\"Crit. care med\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"33\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2266\";s:8:\"\u0000*\u0000epage\";s:4:\"2277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-3493\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"VINCENT\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Jean-Louis\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:17:\"BERNARD, Gordon R\";i:1;s:9:\"WONG, Kar\";i:2;s:15:\"SUNDIN, David P\";i:3;s:15:\"TURLO, Mary Ann\";i:4;s:15:\"JANES, Jonathan\";i:5;s:14:\"BEALE, Richard\";i:6;s:17:\"DOIG, Christopher\";i:7;s:19:\"PUTENSEN, Christian\";i:8;s:23:\"DHAINAUT, Jean-Francois\";i:9;s:16:\"ARTIGAS, Antonio\";i:10;s:18:\"FUMAGALLI, Roberto\";i:11;s:15:\"MACIAS, William\";i:12;s:16:\"WRIGHT, Theressa\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCMDC7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1097\/01.CCM.0000181729.46010.83\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Critical care medicine\";s:9:\"\u0000*\u0000stitle\";s:14:\"Crit. care med\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"33\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2266\";s:8:\"\u0000*\u0000epage\";s:4:\"2277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-3493\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"VINCENT\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Jean-Louis\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:17:\"BERNARD, Gordon R\";i:1;s:9:\"WONG, Kar\";i:2;s:15:\"SUNDIN, David P\";i:3;s:15:\"TURLO, Mary Ann\";i:4;s:15:\"JANES, Jonathan\";i:5;s:14:\"BEALE, Richard\";i:6;s:17:\"DOIG, Christopher\";i:7;s:19:\"PUTENSEN, Christian\";i:8;s:23:\"DHAINAUT, Jean-Francois\";i:9;s:16:\"ARTIGAS, Antonio\";i:10;s:18:\"FUMAGALLI, Roberto\";i:11;s:15:\"MACIAS, William\";i:12;s:16:\"WRIGHT, Theressa\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCMDC7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:34:\"10.1097\/01.CCM.0000181729.46010.83\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1097\/01.CCM.0000181729.46010.83\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Critical care medicine\";s:9:\"\u0000*\u0000stitle\";s:14:\"Crit. care med\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"33\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2266\";s:8:\"\u0000*\u0000epage\";s:4:\"2277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-3493\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"VINCENT\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Jean-Louis\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:17:\"BERNARD, Gordon R\";i:1;s:9:\"WONG, Kar\";i:2;s:15:\"SUNDIN, David P\";i:3;s:15:\"TURLO, Mary Ann\";i:4;s:15:\"JANES, Jonathan\";i:5;s:14:\"BEALE, Richard\";i:6;s:17:\"DOIG, Christopher\";i:7;s:19:\"PUTENSEN, Christian\";i:8;s:23:\"DHAINAUT, Jean-Francois\";i:9;s:16:\"ARTIGAS, Antonio\";i:10;s:18:\"FUMAGALLI, Roberto\";i:11;s:15:\"MACIAS, William\";i:12;s:16:\"WRIGHT, Theressa\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCMDC7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1097\/01.CCM.0000181729.46010.83\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Critical care medicine\";s:9:\"\u0000*\u0000stitle\";s:14:\"Crit. care med\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"33\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2266\";s:8:\"\u0000*\u0000epage\";s:4:\"2277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-3493\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"VINCENT\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Jean-Louis\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:17:\"BERNARD, Gordon R\";i:1;s:9:\"WONG, Kar\";i:2;s:15:\"SUNDIN, David P\";i:3;s:15:\"TURLO, Mary Ann\";i:4;s:15:\"JANES, Jonathan\";i:5;s:14:\"BEALE, Richard\";i:6;s:17:\"DOIG, Christopher\";i:7;s:19:\"PUTENSEN, Christian\";i:8;s:23:\"DHAINAUT, Jean-Francois\";i:9;s:16:\"ARTIGAS, Antonio\";i:10;s:18:\"FUMAGALLI, Roberto\";i:11;s:15:\"MACIAS, William\";i:12;s:16:\"WRIGHT, Theressa\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCMDC7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1097\/01.CCM.0000181729.46010.83\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Critical care medicine\";s:9:\"\u0000*\u0000stitle\";s:14:\"Crit. care med\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"33\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2266\";s:8:\"\u0000*\u0000epage\";s:4:\"2277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-3493\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"VINCENT\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Jean-Louis\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:17:\"BERNARD, Gordon R\";i:1;s:9:\"WONG, Kar\";i:2;s:15:\"SUNDIN, David P\";i:3;s:15:\"TURLO, Mary Ann\";i:4;s:15:\"JANES, Jonathan\";i:5;s:14:\"BEALE, Richard\";i:6;s:17:\"DOIG, Christopher\";i:7;s:19:\"PUTENSEN, Christian\";i:8;s:23:\"DHAINAUT, Jean-Francois\";i:9;s:16:\"ARTIGAS, Antonio\";i:10;s:18:\"FUMAGALLI, Roberto\";i:11;s:15:\"MACIAS, William\";i:12;s:16:\"WRIGHT, Theressa\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCMDC7\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatment\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
